Jingying Xu, Ph.D. - Publications

Affiliations: 
2010 Neuroscience University of Southern California, Los Angeles, CA, United States 
Area:
Oncology

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Wu SG, Xu JY, Lei J, Hu M, Zhou J. Correction: Wu . Tumor-Suppressor Gene Transmembrane Protein 98 Promotes Proliferation and Inhibits Apoptosis in Ovarian Cancer. Frontiers in Bioscience-Landmark. 2022; 27: 210. Frontiers in Bioscience (Landmark Edition). 28: 90. PMID 37664929 DOI: 10.31083/j.fbl2707210corr  0.399
2022 Wu SG, Xu JY, Lei J, Hu M, Zhou J. Tumor-Suppressor Gene Transmembrane Protein 98 Promotes Proliferation and Inhibits Apoptosis in Ovarian Cancer. Frontiers in Bioscience (Landmark Edition). 27: 210. PMID 35866395 DOI: 10.31083/j.fbl2707210  0.336
2022 Zhu T, Wang T, Feng Z, Gao F, Zhang J, Jin C, Tian H, Xu J, Chen H, Ou Q, Wang J, Xu G, Lu L. Glia Maturation Factor β as a Novel Independent Prognostic Biomarker and Potential Therapeutic Target of Kidney Renal Clear Cell Carcinoma. Frontiers in Oncology. 12: 880100. PMID 35860559 DOI: 10.3389/fonc.2022.880100  0.309
2017 Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, et al. Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. 8: 52193-52210. PMID 28881723 DOI: 10.18632/Oncotarget.13386  0.727
2017 Xu J, Ren X, Pathania AS, Fernandez GE, Tran A, Zhang Y, Moats RA, Shackleford GM, Erdreich-Epstein A. PID1 increases chemotherapy-induced apoptosis in medulloblastoma and glioblastoma cells in a manner that involves NFκB. Scientific Reports. 7: 835. PMID 28400607 DOI: 10.1038/S41598-017-00947-6  0.75
2016 Erdreich-Epstein A, Singh AR, Joshi S, Vega FM, Guo P, Xu J, Groshen S, Ye W, Millard M, Campan M, Morales G, Garlich JR, Laird PW, Seeger RC, Shimada H, et al. Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget. PMID 27907905 DOI: 10.18632/oncotarget.13386  0.714
2016 Meade JC, Moore ZR, Stuart SH, Cholka A, Boriack RL, Xu J, Erdreich-Epstein A, Rakheja D, Boothman DA, Amatruda JF, Laetsch TW. Abstract B39: NQO1 as a therapeutic target for atypical teratoid/ rhabdoid tumor Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B39  0.711
2015 Xu J, Margol AS, Shukla A, Ren X, Finlay JL, Krieger MD, Gilles FH, Couch FJ, Aziz M, Fung ET, Asgharzadeh S, Barrett MT, Erdreich-Epstein A. Disseminated Medulloblastoma in a Child with Germline BRCA2 6174delT Mutation and without Fanconi Anemia. Frontiers in Oncology. 5: 191. PMID 26380221 DOI: 10.3389/Fonc.2015.00191  0.674
2015 Weingart MF, Roth JJ, Hutt-Cabezas M, Busse TM, Kaur H, Price A, Maynard R, Rubens J, Taylor I, Mao XG, Xu J, Kuwahara Y, Allen SJ, Erdreich-Epstein A, Weissman BE, et al. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget. 6: 3165-77. PMID 25638158 DOI: 10.18632/Oncotarget.3078  0.75
2015 Kaur H, Hütt-Cabezas M, Weingart MF, Xu J, Kuwahara Y, Erdreich-Epstein A, Weissman BE, Eberhart CG, Raabe EH. The chromatin-modifying protein HMGA2 promotes atypical teratoid/rhabdoid cell tumorigenicity. Journal of Neuropathology and Experimental Neurology. 74: 177-85. PMID 25575139 DOI: 10.1097/Nen.0000000000000161  0.727
2015 Chakravadhanula M, Hampton CN, Chodavadia P, Ozols V, Zhou L, Catchpoole D, Xu J, Erdreich-Epstein A, Bhardwaj RD. Wnt pathway in atypical teratoid rhabdoid tumors. Neuro-Oncology. 17: 526-35. PMID 25246426 DOI: 10.1093/Neuonc/Nou229  0.696
2015 Xu J, Margol A, Asgharzadeh S, Erdreich-Epstein A. Pediatric brain tumor cell lines. Journal of Cellular Biochemistry. 116: 218-24. PMID 25211508 DOI: 10.1002/Jcb.24976  0.718
2015 Xu J, Ren X, Shackleford GM, Moats R, Erdreich-Epstein A. BI-04 * PID1 IS A CHEMOTHERAPY SENSITIZER AND CANDIDATE TUMOR SUPPRESSOR IN MEDULLOBLASTOMA Neuro-Oncology. 17: iii3-iii3. DOI: 10.1093/Neuonc/Nov061.10  0.746
2014 Erdreich-Epstein A, Robison N, Ren X, Zhou H, Xu J, Davidson TB, Schur M, Gilles FH, Ji L, Malvar J, Shackleford GM, Margol AS, Krieger MD, Judkins AR, Jones DT, et al. PID1 (NYGGF4), a new growth-inhibitory gene in embryonal brain tumors and gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 827-36. PMID 24300787 DOI: 10.1158/1078-0432.Ccr-13-2053  0.754
2014 Mok S, Koya RC, Tsui C, Xu J, Robert L, Wu L, Graeber TG, West BL, Bollag G, Ribas A. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Research. 74: 153-61. PMID 24247719 DOI: 10.1158/0008-5472.CAN-13-1816  0.334
2014 Xu J, Ren X, Tran A, Shackleford GM, Erdreich-Epstein A. Abstract 3975: PID1, a new growth-inhibitory gene, sensitizes brain tumor cell lines to chemotherapy Cancer Research. 74: 3975-3975. DOI: 10.1158/1538-7445.Am2014-3975  0.772
2014 Xu J, Ren X, Tran A, Erdreich-Epstein A. CB-19 * PID1, A NEW GROWTH-INHIBITORY GENE, SENSITIZES MEDULLOBLASTOMA AND GLIOMA CELL LINES TO CHEMOTHERAPY Neuro-Oncology. 16: v44-v44. DOI: 10.1093/Neuonc/Nou241.18  0.754
2014 Erdreich-Epstein A, Xu J, Ren X. PID1 IS A NOVEL SENSITIZER OF BRAIN TUMOR CELLS TO CHEMOTHERAPY Neuro-Oncology. 16: iii26-iii26. DOI: 10.1093/Neuonc/Nou208.11  0.764
2013 Xu J, Escamilla J, Mok S, David J, Priceman S, West B, Bollag G, McBride W, Wu L. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Research. 73: 2782-94. PMID 23418320 DOI: 10.1158/0008-5472.CAN-12-3981  0.452
2012 Ren X, Xu J, Cooper JP, Kang MH, Erdreich-Epstein A. c-Abl is an upstream regulator of acid sphingomyelinase in apoptosis induced by inhibition of integrins αvβ3 and αvβ5. Plos One. 7: e42291. PMID 22879933 DOI: 10.1371/Journal.Pone.0042291  0.65
2012 Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel JA, Reynolds CP. Novel cell lines established from pediatric brain tumors. Journal of Neuro-Oncology. 107: 269-80. PMID 22120608 DOI: 10.1007/S11060-011-0756-5  0.719
2010 Xu J, Millard M, Ren X, Cox OT, Erdreich-Epstein A. c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin. Blood. 115: 2709-18. PMID 20124512 DOI: 10.1182/Blood-2009-05-223776  0.64
2009 Rosol M, Harutyunyan I, Xu J, Melendez E, Smbatyan G, Finlay JL, Krieger MD, Gonzalez-Gomez I, Reynolds CP, Nelson MD, Erdreich-Epstein A, Blüml S. Metabolism of orthotopic mouse brain tumor models. Molecular Imaging. 8: 199-208. PMID 19728974 DOI: 10.2310/7290.2009.00019  0.691
Show low-probability matches.